BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

Vancouver-based BioNxt Solutions Inc. has announced the signing of a non-binding letter of intent with German company Gen-Plus GmbH & Co KG. This agreement marks a promising collaboration between the parties for various pharmaceutical developments. BioNxt and Gen-Plus previously inked the Master Service Agreement and Cladribine Statement of Work in July 2024.

The LOI outlines potential cooperation areas such as intellectual property, prototype development, clinical trial planning, and batch manufacturing. Gen-Plus specializes in certified services and manufacturing for clinical trial supplies. They have facilities in five countries and more than 500 employees.

BioNxt is working on a proprietary ODF Cladribine dosage form for the multiple sclerosis market. Cladribine tablets are already approved in over 75 countries and generate over one billion USD in annual sales. BioNxt has filed provisional patents for its Cladribine ODF, with full applications expected by late 2024, aiming for patent protection until 2044.